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Rac1 and RhoA are members of the Rho family of Ras-related proteins and function as regulators of actin
cytoskeletal organization, gene expression, and cell cycle progression. Constitutive activation of Rac1 and
RhoA causes tumorigenic transformation of NIH 3T3 cells, and their functions may be required for full Ras
transformation. The effectors by which Rac1 and RhoA mediate these diverse activities, as well as the
interrelationship between these events, remain poorly understood. Rac1 is distinct from RhoA in its ability to
bind and activate the p65 PAK serine/threonine kinase, to induce lamellipodia and membrane ruffling, and to
activate the c-Jun NH2-terminal kinase (JNK). To assess the role of PAK in Rac1 function, we identified
effector domain mutants of Rac1 and Rac1-RhoA chimeric proteins that no longer bound PAK. Surprisingly,
PAK binding was dispensable for Rac1-induced transformation and lamellipodium formation, as well as
activation of JNK, p38, and serum response factor (SRF). However, the ability of Rac1 to bind to and activate
PAK correlated with its ability to stimulate transcription from the cyclin D1 promoter. Furthermore, Rac1
activation of JNK or SRF, or induction of lamellipodia, was neither necessary nor sufficient for Rac1 trans-
forming activity. Finally, the signaling pathways that mediate Rac1 activation of SRF or JNK were distinct
from those that mediate Rac1 induction of lamellipodia. Taken together, these observations suggest that Rac1
regulates at least four distinct effector-mediated functions and that multiple pathways may contribute to
Rac1-induced cellular transformation.
Rho family proteins constitute a major branch of the Ras
superfamily of GDP-GTP-regulated switches (7). While both
Ras and Rho family proteins are regulators of cell morphology
and growth, they regulate distinct cellular processes. Two func-
tions of Rho family proteins have been well characterized.
First, these proteins regulate actin cytoskeleton organization
(8). Microinjection studies have established that Rho proteins
can act in concert and function in a cascade where CDC42Hs
stimulates filopodium formation and also causes activation of
Rac-mediated lamellipodium induction and Rac1 in turn
causes activation of Rho-mediated stress fiber and focal adhe-
sion formation (34, 43, 44).
Second, Rho proteins are regulators of gene expression (53).
Unlike Ras, Rho family proteins do not activate the p42/p44
mitogen-activated protein kinases (MAPKs). Instead, Rac1
and CDC42Hs potently stimulate activity of kinases in the Jun
N-terminal kinase (JNK; also referred to as stress-activated
protein kinase [SAPK]) and p38 families (11, 33, 36). Interest-
ingly, RhoA does not directly stimulate these pathways. Rac1,
RhoA, and CDC42Hs also stimulate the activity of the serum
response factor (SRF) which complexes with ternary complex
factor (TCF)/Elk proteins to stimulate transcription of genes
with serum response elements (SREs) in their promoter-en-
hancer regions (e.g., the c-fos promoter) (19). Importantly, the
activation of SRF by Rac and CDC42Hs is not RhoA depen-
dent; hence, these signals converge at an as-yet-uncharacter-
ized point downstream.
More recent evidence points to an involvement of Rho fam-
ily proteins in events beyond cytoskeletal remodelling. Simi-
larly to the prototype Ras, Rho family proteins induce tumor-
igenic transformation of rodent fibroblasts (2, 24, 37, 39–41,
52). Furthermore, Rac1 and RhoA appear to be required for
Ras transformation and presumably are components of a cas-
cade downstream of Ras, although the linear cascade does not
appear to be as well defined as in the control of cytoskeletal
rearrangements (24, 39, 41). Rac1 can also confer an invasive
phenotype and possibly metastatic potential to lymphocytes
and may therefore be involved in multiple aspects of tumori-
genesis (32). However, despite evidence for their involvement
in transformation, the mechanism whereby Rho family pro-
teins mediate transformation is presently unresolved.
Recently, two clues to the nature of Rac involvement in
cellular transformation have been reported. One possible
mechanism is based on the fact that Rac and Rho proteins are
regulators of the expression of growth-promoting genes. The
activation of the JNK and p38 kinase cascades by Rac stimu-
lates the transcriptional activity of c-Jun and ATF-2 (15, 33).
c-Jun, and to a lesser extent other AP-1 proteins, is necessary
for cell cycle progression, and JNK and Jun function are crucial
for cellular transformation by Ras (10, 21, 26). A specific role
for SRF in Rac1 or RhoA transformation has not been de-
fined, but SRF is a crucial mediator of c-fos transcription, and
c-Fos is required for cell cycle progression and Ras transfor-
mation in some fibroblast models as well as being implicated in
human tumorigenesis (20, 26, 45).
A second line of evidence linking Rac to cellular transfor-
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mation is provided by recent studies demonstrating a role for
Rac, Rho, and CDC42Hs in cell cycle progression through the
G1 phase of the cell cycle (36). Constitutively activated mutants
of these three Rho family proteins, as well as of Ras, caused G1
progression and stimulation of DNA synthesis. Thus, it is pos-
sible that cyclin-dependent kinase activation by Rac and cell
cycle progression are mechanistically linked.
Although morphological changes elicited by Ras and Rho
family proteins have been postulated to be an important com-
ponent of the transformed phenotype, the precise contribution
of actin cytoskeletal reorganization to transformation is poorly
understood. Furthermore, the interrelationship between Rac-
induced gene expression and actin reorganization is not
known. It has been suggested that the stimulation of signal
transduction cascades composed of immediate effectors, such
as PAK, as well as distal signaling kinases (JNK/SAPK and
p38) and resultant transcriptional responses might be respon-
sible for Rac-induced morphological changes. In support of
this, studies of Drosophila melanogaster morphogenesis have
suggested a role for the Drosophila homolog, DPAK, in cy-
toskeletal reorganization, a process which may require c-Jun
(16). Alternatively, it is also possible that actin reorganization
promotes the events that lead to changes in gene expression.
It is clear that Ras interacts with multiple downstream ef-
fectors to trigger a complex array of signaling pathways, and
the case with Rho family proteins may be similar. The effec-
tor(s) that mediates Rac1 induction of lamellipodia, activation
of JNK, p38, and SRF, cell cycle regulation, and transforma-
tion is unclear. The best-characterized effectors are the ubiq-
uitously expressed family of serine/threonine kinases known as
PAKs, but it is not known which, if any, Rac function they
mediate. At least three mammalian PAK isoforms have been
isolated: rat p65PAK/h-PAK-1, h-PAK-2, and mPAK-3 (4, 29,
31). Binding of PAKs to Rac and CDC42Hs stimulates their
serine/threonine kinase activity (4, 29).
By virtue of its striking homology with the Saccharomyces
cerevisiae protein Ste20, which is implicated in G protein-as-
sociated pheromone signaling to a MAPK cascade, PAK has
been considered a likely candidate for a link from Rac and
CDC42Hs to mammalian MAPKs (46, 57). Published reports
have implicated p65PAK as the effector responsible in mam-
malian cells for activation of JNK/SAPK and p38 MAPK cas-
cades (3, 38, 56). A linear pathway has thus been proposed,
leading from Rac through the effector PAK to MEKK, MKK4
(SEK), and MKK3 and, eventually, JNK and p38. However,
the direct target(s) of PAK is unknown, and overexpression of
wild-type or activated PAKs activates JNK and p38 activity
significantly less than Rac or CDC42Hs in some studies and
not at all in others (3, 33, 56).
Recent studies have demonstrated that the use of Ras ef-
fector domain mutants, which are differentially impaired in
downstream signaling activities, is a powerful approach for
deciphering the specific signaling pathways critical for Ras
transformation (23, 25, 55). For example, mutants of Ras
which no longer bind to Raf but maintain signaling through
other pathways and maintain transforming activity have been
isolated (25). We have utilized an analogous approach to iden-
tify the critical sequelae of Rac activation required for Rac1-
mediated actin cytoskeleton remodelling, signaling, transcrip-
tional activation, and transformation. Our observations reveal
that Rac1 binding to PAK is dispensable for Rac induction of
lamellipodia, activation of JNK and SRF, and transformation
of NIH 3T3 cells. However, PAK binding correlated with the
ability of Rac1 to stimulate transcription from the cyclin D1
promoter. Additionally, Rac causes changes in the actin cy-
toskeleton by activation of pathways distinct from those that
mediate Rac regulation of gene expression. Finally, since no
one Rac action directly correlated with Rac1 transforming
activity, we suggest that Rac regulation of cell growth is me-
diated by multiple Rac functions.
MATERIALS AND METHODS
Site-directed mutagenesis of Rac1. The human rac1(61L) cDNA (24) was
subcloned into the BamHI site of pBluescriptSK1 and mutagenized with the
Chameleon kit (Stratagene). Oligonucleotides were produced on an Applied
Biosystems synthesizer with 59 phosphate added. The selection primer was de-
signed to replace the polylinker KpnI site of pBluescriptSK1 with an NdeI site:
59GGG TAC CGG GCC CCC CCA TAT GGT CGA CGG TAT CGA TAA
GC39. Mutagenic oligonucleotides used were as follows: N26D, 59GGA TAT
ATT CTC CAGGAAATG CAT CGG TTG TGT AAC TGA TCAGTAGG39;
E31V, 59GTC AAA GAC AGT AGG GAT ATA CAC TCC AGG AAA TGC
ATT GG39; Y40C, 59AAC ATT GGC AGA GCA ATT GTC AAA GAC39;
N43D, 59CCA TCT ACC ATA ACG TCG GCA GAA TAA TTG TCA AAG
ACA GTA GG39. Mutagenesis was verified by dideoxy sequencing. The use of a
random mutagenesis protocol to identify mutants of Rac12V that are impaired
in effector binding has been described elsewhere (22).
cDNA sequences encoding Rac-Rho chimeras were generated by utilizing the
unique conserved PvuII site at amino acid 59 of Rac1 and that at amino acid 61
of RhoA. The amino acid sequences of Rac and Rho are identical from this point
through amino acid 73; hence, these chimeras are labeled Rac73Rho and
Rho73Rac to allow comparison with previous analyses (13). In each case, the
carboxy-terminal sequence bears an activating mutation in the switch II region
(61L in Rac1 and 63L in the RhoA sequence). Chimeric constructs were verified
by sequencing.
Expression vectors and reporter plasmids. rac1(61L) sequences were sub-
cloned into the expression vector pCGN-hyg (gift of M. Ostrowski), which is
derived from the vector pCGN, for expression in COS-7 cells and NIH 3T3 cells
(49). pCGN-hyg constructs encode the hemagglutinin (HA) epitope tag down-
stream of the cytomegalovirus promoter, in frame with the amino terminus of
Rac1 sequences. rhoA(63L) and wild-type and mutant rac1(61L) cDNA se-
quences were also subcloned into pGEX4T (Pharmacia) for bacterial expression
as glutathione S-transferase (GST) fusion proteins. Sequences encoding Rac61L,
RhoA(63L), Rac73Rho, and Rho73Rac were also subcloned into pcDNA3 (In-
vitrogen) for expression in mammalian cells. rac1(12V) sequences were sub-
cloned into pcDNA3 (Rac12V/33N, Rac12V/35S, and Rac12V/40H) or pCGT
(Rac12V/33N, Rac12V/37L, and Rac12V/40H) (50). The sequence encoding
Rho73Rac was cloned into the LexA vector pBTM116, and all other rac se-
quences were cloned into the LexA vector pLEVVJ10 for yeast two-hybrid
analysis. Sequences encoding the putative Rac1 effectors PAK-3, ROK, and
POR-3 as well as Raf-1 were subcloned into GAL4 activation domain expression
vectors for yeast two-hybrid analysis as previously described (50). pJ3HPAK-1
and pCMV6M-PAK-1 encode amino-terminal HA and Myc epitope-tagged
PAK-1, respectively (gifts of J. Chernoff). pZIP-raf/CAAX consists of c-Raf-1
coding sequences with the 18-amino-acid K-Ras4B carboxy-terminal plasma
membrane targeting sequence linked in frame to the carboxy terminus of full-
length Raf-1 (35).
A reporter for analysis of SRF activity was generated with a mutant SRE
sequence which no longer binds TCF (Elk/SAP) proteins (19). Oligonucleotides
representing the mutant SRE were synthesized with SalI linkers, phosphorylated
with T4 polynucleotide kinase (BRL), annealed, and ligated, and multimers of
this sequence were isolated from nondenaturing polyacrylamide gels. A dimer of
the mutant SRE was cloned into the unique SalI site of the minimal reporter
construct D56Fos-dE-Luciferase (14). The sequences of the mutant SRE oligo-
nucleotides used were as follows: 59TCG ACT GTA CTG TAT GTC CAT ATT
AGG ACA TCT G39 (top) and 59TCG ACA GAT GTC CTA ATA TGG ACA
TAC AGT ACA G39 (bottom). Cyclin D1-luciferase (CD1-Luc) consists of
sequences from 2963 of human cyclin linked to luciferase (1). 5XGal-luciferase
and Gal-Jun(1-223) have been previously described (48). Flag epitope-tagged
expression vectors for JNK1 and p38 and the bacterial expression vector GST-
Jun(1-79) were provided by M. Karin.
Yeast two-hybrid binding assay. The yeast strains and media for performance
of the yeast two-hybrid binding analyses have been described previously (50).
Rac1 sequences (61L, 61L/26D, 61L/31V, 61L/43D, Rac73Rho, and Rho73Rac)
were expressed as fusions between the Rac1 protein and the DNA-binding
domain of LexA (LBD). Rac1 binding partners were expressed as GAL4 acti-
vation domain fusions containing the Rac1 binding sequences from PAK-3,
ROK, POR-3, and the Ras binding sequence from Raf-1 (50, 51). POR-3 was
identified by yeast two-hybrid screening for Rac1-interacting proteins that exhibit
properties of a Rac1 effector target by procedures that we have described pre-
viously (50). Briefly, LBD Rac12V was used as bait to screen a Jurkat cDNA
library fused to the GAL4 activation domain of pGADGH. Sequence analysis of
a partial clone of approximately 600 bp revealed that POR-3 did not show any
homology with any known proteins. As described previously, ROKa is a Rac1-
and RhoA-interacting protein (5, 28). Interactions between Rac-LexA DNA-
binding domain fusions and the GAL4 activation domain fusions were assessed
in the yeast reporter strain L40 and quantitated in a liquid b-galactosidase assay
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as previously described (50). Values (mean 6 standard deviation of triplicate
determinations) are given in Miller units in Fig. 1 (18).
Cell culture, transfection, and transformation assays. COS-7 and NIH 3T3
cells were maintained in Dulbecco’s modified Eagle medium (DMEM; high
glucose) supplemented with 10% fetal bovine serum or newborn calf serum,
respectively. Transfection of COS-7 cells was achieved with the Lipofectamine
reagent (GIBCO/BRL) as described by the manufacturer. Thirty hours after
transfection, the medium was changed to DMEM containing 0.5% fetal bovine
serum, and after 14 h of incubation, lysates were prepared as previously de-
scribed (42). NIH 3T3 cells were transfected by calcium phosphate coprecipita-
tion as previously described, allowed to recover for 30 h, and starved in DMEM
with 0.5% newborn calf serum for 14 h before lysate preparation (9, 17, 54).
Focus formation assays were performed with NIH 3T3 cells exactly as described
previously (9). For cooperation with Raf/CAAX, cells seeded into 60-mm-diam-
eter tissue culture dishes were cotransfected with 10 ng of pZIP-rafCAAX and
500 ng of rac1 or rhoA expression vector. Cognate empty vectors of each plasmid
were employed as controls. After 12 to 14 days of growth, the plates were stained
with 0.4% crystal violet and photographed. NIH 3T3 cells were also stably
transfected with all pCGN-hyg and chimeric pcDNA3 constructs and were uti-
lized in soft agar assays as previously described (9). Cells used in these assays
represent pooled populations of .50 individual colonies selected in hygromycin
(200 mg/ml) or G418 (400 mg/ml). Expression of the mutant proteins was con-
firmed by Western blotting (data not shown). Cells (5 3 103/cm2) were seeded
into 60-mm-diameter plates in growth medium containing 0.3% soft agar, and
colonies were photographed after 18 days on a Nikon phase-contrast microscope
at 340 magnification.
Transient-expression reporter gene assays.Analysis of luciferase expression in
transiently transfected NIH 3T3 cells was performed as described with enhanced
chemiluminescence reagents (Amersham) and a Monolight 2010 luminometer
(Analytical Luminescence, San Diego, Calif.) (17). Two separate plasmid prep-
arations of each mutant were analyzed to ensure reproducibility of data. All
assays were performed in duplicate, and results shown represent the mean (6
standard error of the mean [SEM]) of at least three independent assays for each
reporter gene with each mutant. To allow comparison of the mutants in different
expression vectors, results are expressed as a percentage of maximal stimulation,
where the activated Rac1 (Rac12V or Rac61L) equals 100%.
Immunoprecipitation and in vitro kinase assays. PAK-1 activity was analyzed
in COS-7 cells following transfection of HA or Myc epitope-tagged PAK-1 and
the various Rac expression vectors. Cells were transfected in 100-mm-diameter
plates, and after starving for 14 h, lysates were collected in 1 ml of lysis buffer
containing protease and phosphatase inhibitors (42). PAK was immunoprecipi-
tated with anti-HA (BAbCO) or anti-myc (9E10; Santa Cruz Biotechnology)
antibody as indicated, and the kinase activity was measured by using 4 mg of
myelin basic protein (MBP) as the substrate. In vitro kinase reactions were
carried out for 20 min at 308C and stopped with 23 sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer. Proteins were
fractionated on SDS–12.5% PAGE and blotted to Immobilon filters (Millipore).
The blots were dried and exposed to film for 1 to 3 h and then subjected to
quantitation on a PhosphorImager (Molecular Dynamics). The blots were sub-
sequently probed with antibodies to the appropriate epitope to visualize expres-
sion of the PAK construct. A tenth volume of the lysate used in the immuno-
precipitations was fractionated on SDS–15% PAGE and probed with the
appropriate antibody (anti-T7 [Novagen] or anti-HA [BAbCO]) to visualize
Rac1 levels in the lysates. Following incubation with horseradish peroxidase-
labelled anti-mouse secondary antibodies, Western blots were developed with
enhanced chemiluminescence reagents (Amersham). These methods were also
employed to analyze JNK-1 and p38 activity with the anti-Flag antibody (Kodak/
IBI) and 2 mg of GST-Jun(1-79) or GST-ATF2(1-254), respectively, as the
substrate.
Analysis of lamellipodium formation. Methods for analysis of lamellipodium
formation were similar to those described in reference 18. Porcine aortic endo-
thelial (PAE) cells (gift of Lena Claesson-Welsh) were injected with pCGN
constructs at 1 mg/ml and with pCGT or pcDNA3 constructs at 2 mg/ml. Con-
centrations were chosen in order to obtain approximately 50% lamellipodium
induction in the control (Rac61L or Rac12V) cells. After injection, cells were
starved in serum-free medium and fixed after 13 to 15 h. Rac-injected cells were
identified by coexpressed green fluorescent protein (GFP) (Green Lantern;
BRL) injected at 25 mg/ml. The actin cytoskeleton was visualized by incubation
with rhodamine-phalloidin (1 mg/ml) for 10 min. Cells expressing GFP which
exhibited obvious lamellipodia were counted as positive. The standard error of
these measurements was determined by dividing the coverslips into three areas
and determining the mean of the three counts.
RESULTS
Effector domain mutants of Rac1 exhibit differential binding
and activation of PAK. Rac1 and CDC42Hs, but not RhoA,
bind and cause activation of the serine/threonine kinase PAK
(4, 29). To address the specific contribution of PAK to the
diverse signaling and biological activities of Rac1, we mutated
specific residues in the Rac61L effector domain (spanning res-
idues 25 to 45) that are identical to CDC42Hs but distinct from
those seen in the RhoA, RhoB, and RhoC proteins (26D, 31V,
and 43D) (Table 1). We also mutated a tyrosine residue that is
conserved in all Ras superfamily proteins and has been shown
to be important for Ras function (40C) (23, 25, 55). Another
panel of mutants was derived by random mutagenesis of
Rac12V to identify effector domain mutants that show differ-
ential binding to a panel of Rac1 effectors (PAK-3, POR-3, and
ROK) in yeast two-hybrid analyses (33N, 35S, 37L, and 40H)
(Table 2) (22). The ability of each Rac1 mutant to interact with
PAK was determined in yeast two-hybrid binding analyses and
in in vitro binding assays with bacterially expressed mutant
proteins.
Several mutants showed impaired PAK interaction (Table
2). In particular, mutation of activated Rac1 at amino acid 43
to the cognate RhoA amino acid (Rac61L/43D) completely
blocked the ability of Rac1 to interact with PAK in the yeast
two-hybrid assay (Fig. 1A). Interestingly, this mutant was not
compromised in its ability to interact with two other candidate
Rac effectors, POR-3 and ROKa (Fig. 1A). This mutant was
also severely impaired in PAK binding as determined by in
vitro binding assays utilizing bacterially expressed Rac1 and
wild-type PAK expressed in COS-7 cells (data not shown).
Finally, neither wild-type nor mutant Rac1 proteins showed
any ability to bind to the Ras effector, Raf-1 (Fig. 1A).
We also determined the ability of each mutant to activate
PAK in vivo in transient-overexpression assays using COS-7
cells (Fig. 1B and C; Table 2). These analyses showed that all
TABLE 1. Ras and Rho family effector domain: correlation with biological and biochemical phenotype
Protein
Phenotype for Ras residue no. or property:
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Na Tb Pc Jd Se
RasH, K, and N Q N H F V D E Y D P T I E D S Y R K Q V V 11 NDg 2 1 1
RhoA, B, and C K D Q/E *f P E V * V * * V F E N * I/V A D I E 1 2 2 2 11
Rac1 and 2 T * A * P G * * I * * V F * N * S A N * M 1 1 1 11 11
CDC42Hs T * K * P S * * V * * V F * N * A V T * M 2 ND 1 11 11
a NIH 3T3 transformation (references 24 and 39 to 41 and unpublished observation). 11, .1,000 foci per mg of DNA; 1, ,100 foci per mg of DNA; 2, no
focus-forming activity in NIH 3T3 assays.
b BW5147 T-cell invasiveness (32). 1, induction of invasion; 2, no induction of invasion.
c p65 PAK binding (29).
d JNK activation (11, 33, 36). 11, strong activation; 1, weak activation; 2, no activation.
e SRF activation (19). 11, strong activation; 1, weak activation.
f *, identity with Ras.
g ND, not determined.
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mutants were fully capable of activating PAK catalytic activity
except Rac61L/40C and Rac12V/40H, which were severely im-
paired, and Rac61L/43D and Rac12V/37L, which were sub-
stantially impaired. Since other single amino acid substitutions
(e.g., 31V) failed to impair PAK binding and activation, it
suggests that multiple residue differences between Rac1/
CDC42Hs and RhoA effector domains determine recognition
by PAK (Table 1).
Interaction with PAK-1 is neither necessary nor sufficient
for Rac1 transforming activity. PAK-1 is the best-character-
ized candidate effector for Rac1, and several studies have im-
plicated PAK in signaling downstream from Rac (3, 4, 29, 38,
46, 56, 57). To determine if Rac1 interaction with PAK was
important for Rac1 transforming activity, we evaluated the
transforming potential of each Rac1 mutant with two assays.
First, previous studies have shown that coexpression of Rac1
with activated Raf-1 (e.g., Raf/CAAX or RafY340D) causes a
synergistic enhancement of focus-forming activity in NIH 3T3
cells (24, 41). Utilizing the mutants described above, we found
that the Rac61L/40C and Rac12V/40H mutants, which were
severely impaired in PAK interaction and activation, were still
capable of cooperative focus-forming activity when coex-
pressed with Raf/CAAX in NIH 3T3 cells (Fig. 2A and Table
2). In contrast, although Rac61L/26D bound and activated
PAK as well as nonmutated Rac1 (Rac12V or Rac61L) in
two-hybrid analysis and in vitro binding studies, it showed
significantly impaired transforming activity (Fig. 2A and data
not shown).
We also used the ability of activated Rac1 alone to promote
anchorage-independent growth (24) to determine the conse-
quences of each mutation to Rac1 transforming potential. For
these analyses, we utilized pooled populations of multiple
drug-resistant colonies of NIH 3T3 cells stably expressing each
Rac1 mutant protein. Interestingly, consistent with the failure
of these mutants to cooperate with Raf/CAAX in focus for-
mation assays (Fig. 2A), we found that cells expressing the
Rac61L/26D and Rac61L/43D mutants were unable to support
growth in soft agar (Fig. 2B). Overall, we observed a direct
relationship between these two transformation assays with all
Rac1 mutants. Finally, cell lines expressing these mutants were
also severely impaired in their ability to form foci of trans-
formed cells in secondary focus formation assays (data not
shown). Thus, we conclude that Rac1 interaction with PAK-1
is neither necessary nor sufficient to confer a transformed
phenotype on NIH 3T3 cells.
PAK is dispensable for Rac1 activation of JNK. Several
studies have implicated PAK in the activation of JNK by Rac.
For example, kinase-inactive, dominant negative alleles of
PAK blocked JNK activation by Rac, raising the possibility that
PAK is the link between Rac and MEKK, and hence the JNK
pathway (33). We have found, however, that both wild-type
and kinase-inactive PAKs can block Rac signaling to the JNK
pathway, suggesting instead that PAK overexpression is block-
ing the interaction of the bona fide effector for JNK activation
(data not shown). Other studies have suggested that activated
PAK alone is sufficient to enhance JNK activity (3, 38, 56). To
address this question, we analyzed Rac1 effector domain mu-
tants as well as Rac-Rho chimeras for their ability to activate
JNK in transient-expression assays in COS-7 cells as well as in
functional assays utilizing a Gal4-Jun fusion protein in tran-
TABLE 2. Properties of Rac1 effector domain mutants and Rac1-RhoA chimeras
Proteina
Value
Focus formationb Lamellipodiac Gal-Jund JNKe
PAK
SRFh Cyclin D1i
In vivo kinasef Two hybridg
Rac12V 111 111 111 111 1 1 111 111
Rac61L 111 111 111 111 1 1 111 111
Rac61L/26D 1 111 111 11 1 1 1111 11
Rac61L/31V 11 1 11 111 1 1 11 111
Rac12V/33N 111 ND 111 111 11 11 1 1111
Rac12V/35S 6 ND 1 6 ND 2 6 6
Rac12V/37L 11 2 6 1 6 1 2 6
Rac61L/40C 111 111 6 2 2 2 6 6
Rac12V/40H 111 111 6 2 2 2 6 6
Rac61L/43D 1 111 111 111 6 2 111 1
RhoA(63L) 11 SFs 6 2 2 2 111 1111
Rac73Rho 1 SFs 6 2 2 2 111 6
Rho73Rac 1111 11 111 11 2 2 111 11111
a Oligonucleotide-directed or random mutagenesis of rac1(61L) or rac1(12V) cDNA sequences, respectively, was employed to generate mutant sequences encoding
effector domain mutants of constitutively activated Rac1. Chimeric proteins are composed of the N-terminal 73 residues from Rac61L or RhoA(63L) and terminate
with the reciprocal C-terminal amino acids.
b Appearance of transformed foci when cotransfected with pZIP-raf/CAAX in NIH 3T3 (UNC) focus formation assays. 6, ,5 foci per dish (activity seen with
Raf/CAAX alone); 1, 5 to 10; 11, 10 to 20; 111, 20 to 30; 1111, .30. Note that the Rac12V/37L mutant did not cause transformation in the NIH 3T3 (CSHL)
strain (22).
c Induction of lamellipodia in PAE cells. 2, ,5% injected cells with lamellipodia; 1, 5 to 19%; 11, 20 to 35%; 111, .35%; SFs, induction of stress fibers.
d in vivo activation of Gal-Jun transcriptional activity. 6, 1 to 30% of maximal stimulation, where value for Rac61L 5 100%; 1, 30 to 60%; 11, 60 to 80%; 111,
80 to 120%.
e Rac1 activation of JNK1 in transiently transfected COS-7 cells.2,,2-fold activation relative to vector-only control;6, 2- to 4-fold;1, 5- to 8-fold;11, 8- to 12-fold;
111, .12-fold (activity seen with nonmutated Rac12V or Rac61L).
f Rac1 activation of p65 PAK1 in transiently transfected COS-7 cells. 2, ,2-fold activation relative to vector-only control; 6, 2- to 6-fold; 1, 6- to 18-fold; 11,
.18-fold.
g Induction of b-galactosidase activity in yeast two-hybrid analysis. 2, ,2 units of activity; 1, 50 to 70 units; 11, .70 units. Data for Rac12V mutant proteins are
derived from the method of Joneson et al. (22).
h In vivo activation of transcription from an SRF-dependent promoter element upstream of the luciferase gene. 2, ,5% of maximal stimulation, where value for
Rac61L 5 100%; 6, 5 to 25%; 1, 26 to 50%; 11, 51 to 90%; 111, 91 to 120%; 1111, .120%.
i in vivo activation of transcription from the cyclin D1 promoter upstream of the luciferase gene. 6, 6 to 30% of maximal stimulation, where value for Rac61L 5
100%; 1, 31 to 50%; 11, 51 to 90%; 111, 91 to 120%; 1111, 121 to 150%; 11111, .150%.
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FIG. 1. Rac1 effector domain mutants are impaired in PAK binding and activation. (A) Two-hybrid analysis of Rac1 effector domain mutants and Rac-Rho
chimeras. The indicated Rac effector domain mutant or chimeric Rac-Rho protein was expressed as a LexA fusion protein and subjected to yeast two-hybrid binding
analysis with the indicated candidate effector (PAK-3, POR-3, ROK, or Raf expressed as a GAL4 DNA-binding domain fusion protein). b-Galactosidase (b-Gal)
activity was quantitated, and data are expressed as the averages of three determinations (6SEM). (B) PAK activity is differentially stimulated by activated Rac1 effector
domain mutants. COS-7 cells were transfected with an expression vector encoding Myc epitope-tagged wild-type PAK-1, along with the indicated effector domain mutants
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siently transfected NIH 3T3 cells. As described above, Rac61L/
43D is defective in its ability to bind to and activate PAK (Fig.
1A and C). This mutant displayed full activity, however, in
activation of JNK as assessed in both the COS-7 and NIH 3T3
transient-transfection assays (Fig. 3A and C).
Utilizing reciprocal chimeras between Rac1 and RhoA, we
found that neither of these proteins was capable of interacting
with PAK in two-hybrid analyses, nor could they activate PAK
catalytic activity (Fig. 1 and data not shown). This is consistent
with published reports which indicate that multiple effector
regions of Rac are required for interaction with PAK (12).
Surprisingly, the Rho73Rac chimera stimulated JNK-depen-
dent reporter gene activity as well as activated Rac1 (Fig. 3C),
suggesting that RhoA sequences in the amino-terminal region
can substitute effectively for Rac1 sequences in conferring this
phenotype. Therefore, regions outside of the classical amino-
terminal effector domain are involved in effector binding, lead-
ing to JNK and transcriptional activation. Furthermore, these
observations provide further evidence that PAK binding is
dispensable for Rac1 activation of JNK.
Rac1 activation of SRF is neither necessary nor sufficient
for transformation. Rac1 is a strong activator of SRF, but the
contribution of this activation to Rac1 function is not known
(19). Rac1 mutants with amino acid substitutions at position 33
or 40 (Rac12V/33N, Rac12V/40H, and Rac61L/40C) were sig-
nificantly impaired in SRF activation but still retained wild-
type transforming potential (Fig. 4). In addition, Rac12V/37L
was completely impaired in SRF activation yet still retained
significant transforming capability (Table 2). In contrast, the
Rac61L/26D mutant, which activated SRF significantly better
than Rac61L in NIH 3T3 cells (Fig. 4), was impaired in trans-
formation when assessed by focus formation and growth in soft
agar (Fig. 2A and B, Table 2, and data not shown). Thus, Rac
activation of SRF is neither necessary nor sufficient for medi-
ating Rac transforming activity.
Since RhoA can activate SRF but cannot bind PAK, it had
previously been assumed that PAK is not an effector for SRF
activation, although it has been postulated that a PAK might
link all Rho proteins to SRF (53). By using chimeras of Rac61L
and RhoA(63L), it was found that both Rac73Rho and
Rho73Rac activated SRF to the same degree as Rac61L and
RhoA(63L) (Fig. 4). This indicated that Rac1 and RhoA se-
quences are interchangeable in conferring this phenotype in
NIH 3T3 cells and also demonstrated that the Rac73Rho chi-
mera, which is severely impaired in JNK activation (Fig. 3C), is
biologically active in these cells. The differential activation of
JNK and SRF by effector domain mutants as well as Rac-Rho
chimeras further indicated that the JNK and SRF pathways are
mediated by distinct effectors binding to Rac1.
Rac1 interaction with PAK, induction of signaling cascades,
and transformation are distinct from induction of lamellipo-
dia. To assess the relationship between JNK and SRF activa-
tion and induction of lamellipodia, we measured the ability of
effector domain mutants and chimeras to induce lamellipodia
in PAE cells. Both Rac61L/40C and Rac12V/40H mutants
were completely negative for PAK binding and activation and
severely impaired in JNK and SRF activation, yet lamellipodia
were induced with the same frequency as that seen with
Rac61L (Fig. 5). In contrast, Rac61L/31V bound and activated
PAK and activated JNK, yet it induced lamellipodia to only
20% the level of activated Rac1 (Fig. 5). Thus, Rac interaction
with PAK and activation of JNK and SRF (as well as down-
stream targets [see below]) are activities distinct from those
that promote Rac1 induction of lamellipodia.
Both the Rac61L/26D and Rac61L/43D mutants exhibited
strong lamellipodium induction, yet both were impaired in
their transforming capabilities in that they failed to promote
proliferation of NIH 3T3 cells in anchorage-independent con-
ditions (Fig. 2 and 5; Table 2). Therefore, Rac1-induced la-
mellipodium formation alone is not sufficient for full Rac1
transforming activity. Indeed, the Rac61L/31V mutant (par-
tially inhibited in lamellipodium induction) and the Rac12V/
37L mutant (completely incapable of inducing lamellipodia in
these assays) were only mildly suppressed in their abilities to
confer a transformed phenotype on NIH 3T3 cells, as mea-
sured in both focus formation and soft agar colony assays (Fig.
2A and data not shown). Thus, pathways leading to the induc-
tion of lamellipodia are unnecessary for Rac1 transformation
of NIH 3T3 cells.
Stimulation of transcription from the cyclin D1 promoter
correlates with Rac1 binding to PAK. Rac1 function has re-
cently been shown to be necessary for progression through the
G1 phase of the cell cycle (36). Ras is also required for G1
progression, in part by stimulating the expression of cyclin D1
(1). Since oncogenic Ras causes activation of Rac, we evalu-
ated the possibility that Rac1 may stimulate cyclin D1 expres-
sion. For these analyses, we utilized a luciferase gene reporter
plasmid where expression was controlled by the cyclin D1 pro-
moter. Like Ras, activated Rac1 also stimulated cyclin D1
promoter expression (Fig. 6). Since both the 40C and 40H mu-
tants, which retained strong transforming activity and induc-
tion of lamellipodia, were impaired in cyclin D1 activation,
potent cyclin D1 activation is not required for these two Rac1
activities. Additionally, Rac12V/33N was impaired in SRF
but not cyclin D1 stimulation, suggesting that Rac activates
these two events via distinct pathways. With the exception of
Rac61L/43D, we observed a direct correlation between JNK
activation and cyclin D1 stimulation with the different Rac1
effector domain mutants.
In contrast, we observed a strong correlation between Rac1
binding to PAK and activation of the cyclin D1 promoter
(Table 2). For example, we observed that Rac12V/33N exhib-
ited significantly increased binding and activation of PAK and
increased stimulation of cyclin D1 expression. Conversely, the
37L, 40C, 40H, and 43D mutants showed both impaired
PAK interaction and impaired cyclin D1 stimulation. The only
exception to this correlation was seen with the Rho73Rac
chimeric protein, which failed to bind to or activate PAK yet
strongly stimulated cyclin D1 expression. However, since
RhoA(63L) also strongly stimulated cyclin D1 expression,
PAK may serve as the effector that promotes Rac1, but not
RhoA, activation of cyclin D1 expression. Consistent with this
derived by random mutagenesis and yeast two-hybrid screening. (Top panel) PAK was subsequently immunoprecipitated and used in an immune complex kinase assay
with MBP as the substrate. Kinase reaction mixtures were subjected to SDS-PAGE, transferred to Immobilon filters, and exposed to film. (Middle panel) Phospho-
rylation of MBP was determined by PhosphorImager analysis and is expressed as fold activation relative to the level in PAK-plus-vector-transfected cells. The blot was
then probed with antibody to the Myc epitope (a myc) to visualize the PAK levels in each immunoprecipitate. (Bottom panel) The level of Rac1 protein expressed in
each extract was determined by Western blotting and probing with antibodies directed against the T7 epitope (a T7). (C) COS-7 cells were transfected with HA
epitope-tagged wild-type PAK-1 and Rac1 effector domain mutants containing amino acid substitutions based on the Rho sequence. (Top panel) Phosphorylation of
MBP by immunoprecipitated PAK. Activation of kinase activity relative to PAK-plus-empty-vector-transfected cells is indicated (Fold). (Middle panel) PAK levels in
immunoprecipitates were visualized by probing the blot with an antibody directed at the PAK epitope tag (a HA). (Bottom panel) Rac levels in the extracts used for
immunoprecipitation were visualized by Western blotting and probing with antibodies directed against the HA epitope (a HA). Similar results were obtained with the
Myc-tagged PAK-1 expression vector with these mutants (data not shown).
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possibility, we have observed that distinct regions of the cyclin
D1 promoter are required for Rac1 and RhoA stimulation
(data not shown). Thus, PAK may serve as the key effector for
Rac1 activation of cyclin D1.
DISCUSSION
Rac1 is now known to be a regulator of diverse cellular
processes that include the control of actin organization (8),
regulation of gene expression (53), and cell cycle progression
through G1 (36). Rac also regulates cell proliferation and may
function downstream of Ras and be required for full Ras
transformation (24, 41). The effectors by which Rac mediates
these diverse activities, as well as the interrelationship between
these events, remain poorly understood. In particular, while
there is evidence that PAK is an effector for Rac function (3,
13, 56), the precise role of PAK in mediating the diverse
actions of Rac has not been clearly established. We have uti-
lized effector domain mutants of Rac1 to define the role of
PAK in Rac1 function. Unexpectedly, we found that Rac in-
teraction with PAK was dispensable for Rac1 functions except
for cyclin D1 stimulation. Furthermore, we found that the
signaling pathways by which Rac1 regulates gene expression
are distinct from those that regulate actin organization. Finally,
we determined that no single Rac1 activity correlated directly
with Rac1 transforming potential. We conclude that Rac uti-
FIG. 2. Rac1 effector domain mutants and Rac-Rho chimeras show differ-
ential ability to transform NIH 3T3 cells. (A) Focus formation assay. NIH 3T3
cells were transfected with 10 ng of activated c-Raf1 (Raf/CAAX) along with the
empty expression vector, which reproducibly yields a low level of focus formation
in these cells (Raf/CAAX 1 pCGN-hyg). Where indicated, cells were cotrans-
fected with 500 ng of the indicated expression vector and cultured for 14 days
before being stained with 0.4% crystal violet. Results are representative of three
assays performed in triplicate for each mutant. Similar results were obtained in
cotransfection cooperation assays with another activated mutant of Raf
(RafY340D; data not shown). (B) NIH 3T3 cells stably expressing the indicated
Rac1 mutants or empty expression vector were assayed for their ability to pro-
liferate under anchorage-independent conditions. Cells were seeded in growth
medium containing 0.3% agar, and colonies were visualized after 18 days. Cells
were photographed at 340 magnification.
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lizes at least four distinct downstream effector pathways to
mediate its diverse actions (Fig. 7).
Effector domain mutants of Ras have been very useful re-
agents for deciphering the complex nature of Ras signaling
involved in Ras transformation. In particular, the demonstra-
tion that Ras effector domain mutants, which no longer bound
to nor activated the Raf-1 serine/threonine kinase, neverthe-
less retained the ability to cause tumorigenic transformation of
NIH 3T3 cells clearly indicated that Raf-independent effector
pathways were also important for Ras regulation of cell growth
(24, 55). In the present study, we sought to generate equivalent
effector domain mutants of Rac1 which no longer bound to or
activated PAK. Although genetic and biochemical evidence
suggested that PAK was an important effector for Rac activa-
tion of JNK and regulation of actin cytoskeletal organization,
a verification of these roles has not been accomplished. Thus,
our identification of Rac1 mutants, such as the Rac61L/43D
mutant that exhibited greatly impaired PAK binding and acti-
vation, provided important reagents to address this question.
Rather unexpectedly, the loss of PAK interaction did not im-
pair Rac61L/43D induction of lamellipodia or activation of
JNK or SRF. Similar observations were also seen with the
Rho73Rac chimeric protein. Furthermore, a second PAK-bind-
ing deficient mutant, Rac61L/40C, still retained potent trans-
forming activity. Therefore, PAK is also dispensable for Rac1
transforming activity. Thus, Rac1 mediates these actions through
PAK-independent signaling pathways. The role of the Rac
interaction with PAK in Rac1 function is therefore unclear at
present. However, we did observe a direct correlation between
the abilities of Rac1 to activate PAK and to stimulate cyclin
D1 expression. Whereas a mutant of Rac1 with significantly
heightened PAK binding and activation displayed increased
activation, mutants with impaired PAK activation were also
impaired in cyclin D1 activation.
FIG. 3. Activation of JNK1 by Rac1 effector domain mutants. (A) COS-7
cells were transfected with a plasmid expressing Flag epitope-tagged JNK1 to-
gether with the indicated HA epitope-tagged Rac1 mutant or the cognate empty
vector (pCGN-hyg). (Top panel) Cells were serum starved for 14 h, and JNK1
was immunoprecipitated from lysates for analysis in immune complex kinase
assays with GST-Jun(1-79) as the substrate. (Middle panel) Activation of sub-
strate phosphorylation by Rac is expressed relative to the level obtained in
JNK1-plus-vector-transfected cells (Fold). Membranes were subsequently
probed with anti-Flag antiserum to visualize JNK1 levels in the immunoprecipi-
tates. (Bottom panel) Rac levels were determined by Western blotting as for Fig.
1. Data shown are representative of three independent experiments. (B) COS-7
cells were transfected as for panel A, but with the indicated mutants expressed
as T7-tagged proteins. JNK1 activity (top panel) and JNK1 levels (middle panel)
were determined as for panel A; Rac levels were determined by probing Western
blots of extracts with T7 epitope antiserum (bottom panel). Data shown are
representative of three independent experiments. (C) JNK-dependent transcrip-
tional activation by Rac1 effector domain mutants and Rac-Rho chimeras. NIH
3T3 cells were transiently transfected with Gal-Jun(1-223), composed of the
yeast Gal4 DNA-binding domain fused to the amino-terminal activation domain
of the c-Jun protein (0.25 mg), and the reporter construct 5XGal-luciferase (2.5
mg). This reporter system provides a functional readout for total cellular JNK
activity. Cells were cotransfected with the empty expression vector or the indi-
cated Rac mutant (0.5 mg), cultured for 30 h, and then serum starved (0.5% calf
serum) for 14 h before extract preparation. Luciferase activity was determined
and is expressed as the percentage of activation relative to the level of activation
(100%) seen with Rac61L and Rac12V. Average activation by activated (non-
mutated) Rac1 was 18.6-fold in these assays. Data shown are representative of
three independent experiments for each mutant performed in duplicate.
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Our observation that Rac interaction with PAK was dispens-
able for activation of JNK contrasts with previous observations,
where PAK was suggested to be required for this Rac activity
(3, 56). Furthermore, a PAK dominant negative was shown to
block Rac activation of JNK (33). However, as suggested by
the authors of that study, since the PAK dominant negative
constituted the GTP-dependent Rac-binding domain of PAK,
its activity may be nonspecific in that it is likely to block Rac
interaction with PAK as well as with other candidate effectors.
Thus, this does not provide definitive evidence for the involve-
ment of PAK in Rac activation of JNK. Finally, the limited
ability of constitutively activated PAKs to activate JNKs sug-
gests that Rac may cause JNK activation primarily through
FIG. 4. Activation of SRF by Rac1 effector domain mutants and Rac-Rho
chimeras in NIH 3T3 cells. Cells were cotransfected as for Fig. 3C with the
reporter construct (SREm)2-luciferase to measure Rac1 activation of SRF, ei-
ther with the empty expression vector or with one encoding the indicated Rac
mutant. Average activation by nonmutated Rac1 [Rac12V or Rac61L], relative
to empty-vector-plus-reporter-transfected controls, was 67-fold, and data are
expressed as described in the legend to Fig. 3C. Data shown are representative
of three independent experiments performed in duplicate for each mutant.
FIG. 5. Lamellipodium induction in PAE cells by Rac1 mutants and chime-
ras. PAE cells were microinjected with Rac1 expression constructs as indicated,
along with a GFP expression vector to identify injected cells. Cells were serum
starved after injection, and lamellipodium formation was assessed at 13 to 15 h
following rhodamine-phalloidin staining. The numbers of cells injected are indi-
cated in brackets. Expression of mutant proteins was confirmed by immunohis-
tochemical staining of cells (data not shown). Data represent mean counts of
lamellipodia in three independent analyses (6SEM).
FIG. 6. Activation of the cyclin D1 promoter by Rac1 mutants and Rac-Rho
chimeras. NIH 3T3 cells were cotransfected with the human cyclin D1-luciferase
reporter construct and the indicated Rac mutant. Results are expressed as for
Fig. 3C and 4. Average activation by Rac1 was 7.2-fold relative to reporter-plus-
empty-vector-transfected controls. Results shown represent the average of at
least three independent experiments performed in duplicate (6SEM).
FIG. 7. Model of Rac1 effector interactions and downstream pathways. Our
data suggest that Rac1 mediates a PAK-dependent pathway that causes stimu-
lation of transcription from the cyclin D1 promoter and three distinct, PAK-
independent effector pathways leading to induction of lamellipodia, activation of
JNK and Jun, and activation of SRF. The effectors for the PAK-independent
pathways are not known.
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PAK-independent pathways. Since Rac61L/43D retained bind-
ing to other candidate Rac effectors (e.g., POR-3 and ROK),
Rac may mediate JNK activation via these or other Rac bind-
ing proteins.
Previous studies showed that Ras function was necessary for
cell cycle progression through G1 (36, 47). While the precise
signaling pathways that mediate this function are not known,
the ability of Ras to stimulate transcription of cyclin D1 sug-
gests one mechanism for this action. Cyclin D1 mRNA levels
are elevated in Ras-transformed cells (6), and Ras stimulates
transcription from the cyclin D1 promoter (1, 27). Recently,
Rho family protein function was also found to be necessary for
G1 progression (36). Thus, it is possible that Ras regulates
G1 progression via a pathway that involves Rac. Consistent
with this, in the present study we observed that constitu-
tively activated Rac1 also stimulated transcription from the
cyclin D1 promoter. However, a recent report showed that
the Raf-MEK-MAPK pathway positively controlled cyclin D1
expression, whereas p38 antagonized this expression (27). One
possible explanation for this apparent difference in their ob-
servations is that their study used a fragment of the cyclin D1
promoter that lacked the responsive element by which Rac
activation of JNK and p38 may cause stimulation of cyclin D1
expression. Instead, our promoter fragment contains an AP-1
site (at 2954 of the human sequence) where JNK activation of
Jun may cause stimulation of cyclin D1 expression (1). In
support of this, when this AP-1 site was mutated, Rac activa-
tion of the reporter was impaired by greater than 50% (data
not shown). As we have described recently, a distinct region of
the cyclin D1 promoter is sensitive to stimulation by MAPKs
(1). In NIH 3T3 cells, activated Rac proteins were significantly
better activators of the cyclin D1-luciferase reporters than ac-
tivated Ras. Therefore, Ras activation of MAPKs and JNKs
constitutes distinct pathways for regulation of cyclin D1 ex-
pression and cell cycle progression.
Although it is clear that Rac1, as well as RhoA and CDC42Hs,
is a regulator of both actin reorganization and gene expression,
whether these two events are controlled by independent or
interrelated signaling events has not been determined. Since
Rac-mediated induction of lamellipodia and membrane ruf-
fling occurs on a time scale of minutes, it has been suggested
that they occur independently of Rac-mediated events in the
nucleus (53). Our observation that the introduction of 40C or
40H mutations into Rac1 resulted in mutant proteins that
retained strong lamellipodium induction yet were greatly im-
paired in their ability to activate JNK and SRF activity or cyclin
D1 transcription demonstrates that the pathways of Rac1-reg-
ulated gene expression characterized to date are not required
for induction of lamellipodia. Furthermore, since the Rac61L/
31V mutant showed impaired lamellipodium induction, with-
out a concomitant loss of JNK activation or cyclin D1 stimu-
lation, Rac regulation of gene expression is not a consequence
of actin reorganization. Thus, we suggest that Rac stimulates
distinct, independent signaling pathways that regulate gene
expression and actin organization.
To date, essentially nothing is known concerning the mech-
anism by which Rho family proteins activate SRF. Since a
substitution at amino acid 33 of Rac1 significantly impaired
SRF activity yet resulted in enhanced PAK activation, SRF
activation is not likely to be mediated through PAK. Addition-
ally, since Rac73Rho activated SRF but not cyclin D1, the
pathways by which Rac mediates these two functions are dis-
tinct.
The mechanism by which Rac causes alterations in cell pro-
liferation and promotes tumorigenic transformation has not
been determined. Unexpectedly, our analyses of a spectrum of
Rac effector domain mutants failed to demonstrate that any
one particular Rac-mediated event was essential for Rac trans-
forming activity. One interpretation of these data is that Rac
transformation is mediated by some as-yet-unidentified Rac
function. Alternatively, it is possible that multiple Rac func-
tions contribute to Rac transformation but that an impairment
in any one may not cause a significant loss of transforming
potential. Support for this second possibility is provided by
studies evaluating the requirement for the Raf-MEK-MAPK
signaling pathway in Ras transformation. The ability of domi-
nant negative mutants of Raf, MEK, and MAPKs to block Ras
transformation supports the important contribution of this ki-
nase cascade to Ras transformation (30). Nevertheless, the fact
that effector domain mutants of Ras that are impaired in the
ability to bind to and activate Raf can still cause potent trans-
formation argues that multiple Ras pathways contribute to Ras
transformation (25, 55). Thus, Rac1 may also cause transfor-
mation by multiple mechanisms.
The ability of mutations in Rac1 amino-terminal sequences,
which are strongly homologous (;70%) to the well-defined
Ras effector domain (Ras residues 26 to 48), to impair Rac
signaling and function has clearly established this region as an
important domain for Rac effector interaction (12). In agree-
ment with previous studies, we also observed that at least one
amino acid substitution in this region impaired each Rac ac-
tivity that we analyzed, although each mutation caused differ-
ential impairment of a particular function. Recent studies with
chimeric proteins between Rac1 and RhoA also identified a
second, carboxy-terminal region of Rac1 (residues 143 to 175)
important for Rac effector function. Diekmann and colleagues
showed that both amino- and carboxy-terminal regions of Rac1
were required for PAK and p67phox binding, as well as for
Rac-induced lamellipodium formation (13). In agreement with
their observations, we also observed that the Rac73Rho chi-
mera did not bind PAK or induce lamellipodia but instead
induced stress fiber formation (Table 2). Furthermore, we ob-
served a loss of JNK activation, suggesting that the effector
required for JNK activation also requires interaction with car-
boxy-terminal Rac sequences. Interestingly, in their studies,
they found that the Rho73Rac chimeric protein lacked biologi-
cal activity in microinjection analyses. Thus, they suggested that
the amino-terminal Rac1 effector sequences cannot be re-
placed functionally by the Rho effector domain sequences. How-
ever, in the present study, we found that Rho73Rac showed the
ability to activate JNK and Jun and to induce lamellipodia.
Rho73Rac also activated cyclin D1 and was potently transform-
ing in NIH 3T3 cells. Thus, our observations suggest that
RhoA amino-terminal sequences can substitute for Rac1 ami-
no-terminal effector sequences to promote Rac-specific func-
tions.
In summary, we have demonstrated that Rac effector do-
main mutants, as well as chimeric proteins between Rac and
Rho, provide important reagents to decipher the complex sig-
naling pathways and activities regulated by Rac. Following the
paradigm established for Ras, it has been anticipated that Rho
family proteins also utilize multiple effectors to mediate their
complex array of functions. Our studies suggest that Rac1
mediates at least four distinct effector pathways, one of which
may involve PAK activation of cyclin D1. Further analyses of
additional Rac effector mutants, coupled with the identifica-
tion of additional Rac effector proteins and their functions, will
be required to fully unravel the complex nature and interplay
of signaling pathways that regulate the actions of Rac and
other Rho family proteins.
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